Microbot Medical announced a collaboration to develop dedicated robotic procedural kits for use in certain neurovascular procedures.

Microbot Medical entered into a strategic collaboration agreement with Stryker, a global medical technology company. The company says it will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System.

“We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space,” says Harel Gadot, chairman, CEO and president of Microbot Medical. “I believe the similarities in our innovation culture, as well as our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is viewed and adopted.”

The company will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures.

The animal feasibility studies to date support the company’s assertion that it will potentially allow physicians to safely and efficiently conduct remote catheter-based vascular procedures, and reduce the risk for radiation exposure, physical strain on the user and Hospital Acquired Infections (HAIs), without the need for cumbersome and expensive capital equipment.